Navigation Links
Angiotech Pharmaceuticals Announces Conference Call and Webcast
Date:2/4/2010

Fourth Quarter and Year End 2009 Financial Results

VANCOUVER, Feb. 4 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ( ANPI, TSX: ANP) will host a conference call discussing its financial results for the fourth quarter and year ended December 31, 2009, on Thursday, March 4, 2010 at 9:00 AM ET (6:00 AM PT).

Dial-in information for the earnings call on March 4, 2010 is as follows:

North America (toll-free): 866.770.7129

International: 617.213.8067

Enter Passcode: 69484239

A live webcast of the earnings call will be available to interested parties through Angiotech's website at www.angiotech.com in the Investors section.

A press release announcing Angiotech's financial results will be issued prior to the call on March 4th at approximately 8:00 AM ET (5:00 AM Pacific).

An archived replay of the call will be available until March 11, 2010.

Replay information is as follows:

North America (toll-free): 888.286.8010

International: 617.801.6888

Enter Passcode: 61713924

About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech ( ANPI, TSX: ANP), please visit our website at www.angiotech.com.

SOURCE Angiotech Pharmaceuticals, Inc.


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
2. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
3. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
4. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
5. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
6. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
7. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
8. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
9. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
10. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
11. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017  In Atlanta, it seems everyone has ... culture intertwine to create an expressive and dynamic community unlike ... energy and contribute to it. With their ... Fairies seeks to carry on that tradition with a ... Atlanta salon is the newest of 13 nationwide ...
(Date:2/23/2017)... ... February 23, 2017 , ... David ... Inventors Recognition Reception at Purdue Research Park of West Lafayette, Indiana. ... recognition of outstanding contributions to, and success with, commercializing discoveries from Purdue research. ...
(Date:2/23/2017)... SAN FRANCISCO , Feb. 23, 2017   ... Beyond Type 1, a not-for-profit advocacy and education group ... a grant from Beyond Type 1 to support ViaCyte,s ... and other insulin-requiring diabetes.  For more ... cell-derived cell replacement therapies with a focus on the ...
(Date:2/22/2017)... , Feb. 22, 2017  PrimeVax Immuno-Oncology, Inc. announced ... presenting at the Annual Biocom Global Life Science Partnering ... at 11:15 AM, at the Torrey Pines Lodge, in ... the organizers at Biocom who have chosen our company, ... of biotechnology companies, investors, and clinical researchers," said Mr. ...
Breaking Biology Technology:
(Date:2/10/2017)... 10, 2017 Research and Markets ... "Personalized Medicine - Scientific and Commercial Aspects" to their ... ... is integrated with therapy for selection of treatment as well ... and prevention of disease in modern medicine. Biochip/microarray technologies and ...
(Date:2/8/2017)... Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... today reported financial results for its quarter and year ended ... quarter of 2016 was $3.9 million compared to $6.9 million ... fourth quarter of 2016 was $0.6 million compared to $2.6 ... the fourth quarter of 2016 was $0.5 million, or $0.02 ...
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
Breaking Biology News(10 mins):